Adjuvant therapy for high-risk renal cell carcinoma patients

Current Urology Reports

Volumn 8, Issue 1, 2007, Pages 19-30

  Kunkle, David A ^b   Haas, Naomi B ^b   Uzzo, Robert G ^a  

^a FOX CHASE CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CARBONATE DEHYDRATASE XI; CPG OLIGODEOXYNUCLEOTIDE; FLUOROURACIL; GELSOLIN; INTERFERON; INTERLEUKIN 2; KI 67 ANTIGEN; MEDROXYPROGESTERONE ACETATE; MONOCLONAL ANTIBODY G250; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLACEBO; PROTEIN P53; SORAFENIB; SUNITINIB; THALIDOMIDE; UNCLASSIFIED DRUG; VIMENTIN;

CANCER ADJUVANT THERAPY; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER STAGING; DISEASE ASSOCIATION; DRUG EFFICACY; HIGH RISK PATIENT; HUMAN; KIDNEY CARCINOMA; NEPHRECTOMY; REVIEW; SURGICAL APPROACH;

ALGORITHMS; CARCINOMA, RENAL CELL; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEPHRECTOMY; NOMOGRAMS; PROGNOSIS; RADIOTHERAPY, ADJUVANT; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT; SURVIVAL ANALYSIS;

EID: 33846850577     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-007-0017-5     Document Type: Review

References (74)

1. Jemal A, Murray T, Ward E, et al.: Cancer statistics, 2005. CA Cancer J Clin 2005, 55:10-30.
2. Cohen HT, McGovern FJ: Renal-cell carcinoma. N Engl J Med 2005, 353:2477-2490.
3. Jayson M, Sanders H: Increased incidence of serendipitously discovered renal cell carcinoma. Urology 1998, 51:203-205.
4. • Lam JS, Shvarts O, Leppert JT, et al.: Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy. J Urol 2005, 173:1853-1862. This article provides a comprehensive review on the topics of current staging modalities, validated prognostic factors, predictive nomograms, molecular markers, and targeted molecular therapies for RCC.
5. Fuhrman SA, Lasky LC, Limas C: Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Path 1982, 6:655-663.
6. Lam JS, Leppert JT, Figlin RA, Belldegrun AS: Role of molecular markers in the diagnosis and therapy of renal cell carcinoma. Urology 2005, 66(Suppl 5A):1-9.
7. Gonzalgo MR, Yegnasubramanian S, Yan G, et al.: Molecular Profiling and Classification of Sporadic Renal Cell Carcinoma by Quantitative Methylation Analysis. Clin Cancer Res 2004, 10:7276-7283.
8. Chawla SN, Crispen PL, Hanlon AL, et al.: The natural history of observed enhancing renal masses: Meta-analysis and review of the world literature. J Urol 2006, 175:425-431.
9. Frank I, Blute ML, Leibovich BC, et al.: Independent validation of the 2002 American Joint Committee on cancer primary tumor classification for renal cell carcinoma using a large, single institution cohort. J Urol 2005, 173:1889-1892.
10. Hefez KS, Fergany AF, Novick AC: Nephron sparing surgery for localized renal cell carcinoma: impact of tumor size on patient survival, tumor recurrence, and TNM staging. J Urol 1999, 162:1930-1933.
11. Moinzadeh A, Gill IS, Finelli A, et al.: Laparoscopic partial nephrectomy. 3-year followup. J Urol 2006, 175:459-462.
12. Gill IS, Remer EM, Hasan WA, et al.: Renal cryoablation: outcome at 3 years. J Urol 2005, 173:1903-1907.
13. Wolf JS Jr, Aronson FR, Small EJ, Carroll PR: Nephrectomy for metastatic renal cell carcinoma: a component of systemic treatment regimens. J Surg Oncol 1994, 55:7-13.
14. Fallick ML, McDermott DF, LaRock D, et al.: Nephrectomy before interleukin-2 therapy for patients with metastatic renal cell carcinoma. J Urol 1997, 158:1691-1695.
15. Wood CG, Huber N, Madsen L, et al.: Clinical variables that predict survival following cytoreductive nephrectomy for metastatic renal cell carcinoma. J Urol 2001, 165:184A.
16. Mickisch GH, Garin A, van Poppel H, et al.: Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001, 358:966-970.
17. Flanigan RC, Salmon SE, Blumenstein BA, et al.: Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal cell cancer. N Engl J Med 2001, 345:1655-1659.
18. Fyfe G, Fisher RI, Rosenberg SA, et al.: Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995, 13:688-696.
19. Motzer RJ, Bander NH, Nanus DM: Renal-cell carcinoma. N Engl J Med 1996, 335:865-875.
20. Negrier S, Escudier B, Lasset C, et al.: Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. N Engl J Med 1998, 338:1272-1278.
21. •• Escudier B, Szczylik C, Eisen T, et al.: Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC)[abstract 4510]. J Clin Oncol 2005, 23(Suppl):1093S. Patients with advanced RCC who had failed previous treatment were randomized to receive surafenib or placebo. The authors found that surafenib significantly prolonged progression-free survival compared with placebo in patients with previously treated advanced RCC, with a favorable safety profile.
22. •• Motzer RJ, Rini BI, Bukowski RM, et al.: Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006, 295:2516-2524. This open-label, single-arm, multicenter clinical trial demonstrated efficacy and a manageable adverse-event profile for sunitinib as a single drug in second-line therapy for patients with cytokine-refractory metastatic clear-cell RCC.
23. • Lam JS, Schvarts O, Leppert JT, et al.: Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system. J Urol 2005, 174:466-472. The authors use the UISS staging system to create an evidence-based postoperative surveillance protocol for localized and locally advanced RCC.
24. Hafez KS, Novick AC, Campbell SC: Patterns of tumor recurrence and guidelines for followup after nephron sparing surgery for sporadic renal cell carcinoma. J Urol 1997, 157:2067-2070.
25. Janzen NK, Kim HL, Figlin RA, Belldegrun AS: Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin N Am 2003, 30:843-852.
26. Drucker BJ: Renal cell carcinoma: current status and future prospects. Cancer Treat Rev 2005, 31:536-545.
27. Kattan MW, Reuter V, Motzer RJ, et al.: A postoperative prognostic nomogram for renal cell carcinoma. J Urol 2001, 166:63-67.
28. Sorbellini M, Kattan MW, Snyder ME, et al.: A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma. J Urol 2005, 173:48-51.
29. Zisman A, Pantuck AJ, Dorey F, et al.: Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol 2001, 19:1649-1657.
30. Zisman A, Pantuck AJ, Wieder J, et al.: Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol 2002, 20:4559-4566.
31. Frank I, Blute ML, Cheville JC, et al.: An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: The SSIGN score. J Urol 2002, 168:2395-2400.
32. Frank l, Blute ML, Cheville JC, et al.: A multifactorial postoperative surveillance model for patients with surgically treated clear cell renal cell carcinoma. J Urol 2003, 170:2225-2232.
33. Lane BR, Kattan MW, Novick AC: Prediction models of renal cell carcinoma. Atlanta, GA. AUA Update Series: 2006; 25:57-67.
34. Kontak JA, Campbell SC: Prognostic factors in renal cell carcinoma. Urol Clin North Am 2003, 30:467-480.
35. Kim HL, Belldegrun AS, Freitas DG, et al.: Paraneoplastic signs and symptoms of renal cell carcinoma: implications for prognosis. J Urol 2003, 170:1742-1746.
36. Bensalah K, Tostain J, Vincendeau S, et al.: Prognostic significance of thrombocytosis in renal cell carcinoma. J Urol, suppl 2004, 171:200, abstract 752.
37. Cangiano T, Liao J, Naitoh J, et al.: Sarcomatoid renal cell carcinoma: biologic behavior, prognosis, and response to combined surgical resection and immunotherapy. J Clin Oncol 1999, 17:523-528.
38. Tsui KH, Shvarts O, Smith RB, et al.: Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria. J Urol 2000, 163:1090-1095.
39. De Peralta-Venturina M, Moch H, Amin M, et al.: Sarcomatoid differentiation in renal cell carcinoma: a study of 101 cases. Am J Surg Pathol 2001, 25:275-284.
40. Uzzo RG, Cherullo EE, Myles J, et al.: Renal cell carcinoma invading the urinary collecting system: implications for staging. J Urol 2002; 167: 2392-2396.
41. Pantuck AJ, Zeng G, Belldegrun AS, Figlin RA: Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway. Clin Cancer Res 2003, 9:4641-4652.
42. Opavsky R, Pastorekova S, Zelnik V, et al.: Human MN/CA9 gene, a novel member of the carbonic anhydrase family: structure and exon to protein domain relationships. Genomics 1996, 33:480-487.
43. •• Leppert JT, Lam JS, Pamuck AJ, et al.: Carbonic anhydrase IX and the future of molecular markers in renal cell carcinoma. BJU Int 2005, 96:281-285. This article reviews the role of CAIX with regard to prognostication, staging, predicting response to immunotherapy, and as a potential therapeutic target.
44. Bui MH, Seligson D, Han KR, et al.: Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res 2003, 9:802-811.
45. • Kim HL, Seligson D, Liu X, et al.: Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma. J Urol 2005, 173:1496-1501. This study uses a tissue array stained for eight molecular markers for RCC and multivariate analysis to identify markers that are independent predictors for disease-specific survival.
46. Staller P, Sulitkova J, Lisztwan J, et al.: Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature 2003, 425:307-311.
47. Bui MH, Visapaa H, Seligson D, et al.: Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinoma. J Urol 2004, 171:2461-2466.
48. Li E, Bestor TH, Jaenisch R: Targeted mutation of the DNA methyltransferase gene results in embryonic lethality. Cell 1992, 69:915-926.
49. Jones PA, Baylin SB: The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002, 3:415-428.
50. Dulaimi E, de Caceres II, Uzzo RG, et al.: Promoter hypermethylation profile of kidney cancer. Clin Cancer Res 2004, 10:3972-3979.
51. Patard JJ, Kim HL, Lam JS, et al.: Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study. J Clin Oncol 2004, 22:3316-3322.
52. Leibovich BC, Han K, Bui MHT, et al.: Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma. Cancer 2003, 98:2566-2575.
53. Motzer RJ, Bacik J, Murphy BA, et al.: Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002, 20:289-296.
54. •• Motzer RJ, Bacik J, Schwartz LH, et al.: Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 2004, 22:454-463. Prognostic factors for survival are analyzed to categorize patients with metastatic RCC into risk groups for clinical studies.
55. Ficarra V, Martignoni G, Lohse C, et al.: External validation of the Mayo Clinic stage, size, grade and necrosis (SSIGN) score to predict cancer specific survival using a European series of conventional renal cell carcinoma. J Urol 2006, 175:1235-1239.
56. •• Lam JS, Leppert JT, Belldegrun AS, Figlin RA: Adjuvant therapy of renal cell carcinoma: patient selection and therapeutic options. BJU Int 2005, 96:483-488. This article reviews the historical and ongoing clinical trials examining adjuvant therapy for high-risk RCC with emphasis on current and future approaches to adjuvant treatment for this patient population.
57. Kjaer M, Frederiksen PL, Engelholm SA: Postoperative radiotherapy in stage II and III renal adenocarcinoma. A randomized trial by the Copenhagen Renal Cancer Study Group. Int J Radiat Oncol Biol Phys 1987, 13:665-672.
58. Kjaer M, Iversen P, Hvidt V, et al.: A randomized trial of postoperative radiotherapy versus observation in stage II and III renal adenocarcinoma. A study by the Copenhagen Renal Cancer Study Group. Scand J Urol Nephrol 1987, 21:285-289.
59. Pizzocaro G, Piva L, Di Fronzo G, et al.: Adjuvant medroxyprogesterone acetate to radical nephrectomy in renal cancer: 5-year results of a prospective randomized study. J Urol 1987, 138:1379-1381.
60. Lam JS, Belldegrun AS, Figlin RA: Advances in immune-based therapies of renal cell carcinoma. Expert Rev Anticancer Ther 2004, 4:1081-1096.
61. Pizzocaro G, Piva L, Colavita M, et al.: Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study. J Clin Oncol 2001, 19:425-431.
62. Adler A, Gillon G, Lurie H, et al.: Active specific immunotherapy of renal cell carcinoma patients: a prospective randomized study of hormono-immuno versus hormono-therapy. Preliminary report of immunological and clinical aspects. J Biol Response Mod 1987, 6:610-624.
63. Galligioni E, Quaia M, Merlo A, et al.: Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and bacillus Calmette-Guerin: five-year results of a prospective randomized study. Cancer 1996, 77:2560-2566.
64. Clark JI, Atkins MB, Urba WJ, et al.: Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. J Clin Oncol 2003, 21:3133-3140.
65. Atzpodien J, Schmitt E, Gertenbach U, et al.: Adjuvant treatment with interleukin-2 and interferon-alpha2a based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: Results of a prospectively randomised Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). Br J Cancer 2005, 92:843-846.
66. •• Jocham D, Richter A, Hoffman L, et al.: Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomized controlled trial. Lancet 2004, 363:594-599. This phase III trial used autologous renal tumor cell vaccine after nephrectomy and showed statistically significant improvement in progression-free survival compared with observation.
67. Lebret T, Watson RW, Fitzpatrick JM: Heat shock proteins: their role in urological tumors. J Urol 2003, 169:338-346.
68. Gordon MS, Manola J, Fairclough D, et al.: Low dose interferon-α2b + thalidomide in patients with previously untreated renal cell cancer: improvement in progression-free survival but not quality of life or overall survival, a phase III study of the Eastern Cooperative Oncology Group (E2898). Proc Am Soc Clin Oncol 2004, 22:4516.
69. •• Sokoloff MH, Daneshmand S, Ryan CW: Current clinical trials in renal cell carcinoma. Urol Oncol 2005, 23:289-292. This article highlights the various ongoing clinical trial efforts focused on the adjuvant setting for patients at high-risk for recurrence or metastasis.
70. Liao SY, Aurelio ON, Jan K, et al.: Identification of the MN/CA9 protein as a reliable diagnostic biomarker of clear cell carcinoma of the kidney. Cancer Res 1997, 57:2827-2831.
71. Wilhelm SM, Carter C, Tang L, et al.: BAY43-9006 exhibits broad-spectrum antitumor activity and targets the raf/ MEK/ERK pathway and receptor tyrosine kinase involved in tumor progression and angiogenesis. Cancer Res 2004, 64:7099-7109.
72. Motzer RJ, Hutson TE, Tomczak P, et al.: Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-α) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2006, 24(Suppl): LBA3.
73. National Cancer Institute: The Surveillance, Epidemiology, and End Results Registry, 1988-2001. http://www.seer. cancer.gov. Accessed September 1, 2006.
74. Messing EM, Manola J, Wilding G, et al.: Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. J Clin Oncol 2003, 21:1214-1222.